Damir Begic
- Hepatology top 2%
- Hepatocellular Carcinoma Treatment and Prognosis 5
- Oncology top 10%
- Colorectal Cancer Treatments and Studies 4
- Cancer Immunotherapy and Biomarkers 4
- Pancreatic and Hepatic Oncology Research 2
- Pathology and Forensic Medicine top 10%
- Cancer Mechanisms and Therapy 2
-
- Cancer Genomics and Diagnostics 2
-
- Ferroptosis and cancer prognosis 2
- Lung Cancer Treatments and Mutations 2
Damir Begic
8 papers receiving 606 citations
Hit Papers
Peers
Comparison fields: 5 of 36
- Hepatology 465
- Oncology 359
- Pathology and Forensic Medicine 154
- Cancer Research 86
- Immunology 101
Countries citing papers authored by Damir Begic
This map shows the geographic impact of Damir Begic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Damir Begic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Damir Begic more than expected).
Fields of papers citing papers by Damir Begic
This network shows the impact of papers produced by Damir Begic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Damir Begic. The network helps show where Damir Begic may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Damir Begic, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2022 | 12 | |
| 2 | 2021 | 17 | |
| 3 | 2020 | 42 | |
| 4 | 2020 | 26 | |
| 5 | CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)breakdown → | 2019 | 497 |
| 6 | 2017 | 11 | |
| 7 | 2016 | 0 | |
| 8 | 2016 | 2 | |
| 9 | 2016 | 5 |
About Damir Begic
Damir Begic is a scholar working on Hepatology, Oncology and Otorhinolaryngology, having authored 9 papers that have together received 612 indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (5 papers), Colorectal Cancer Treatments and Studies (4 papers), Cancer Immunotherapy and Biomarkers (4 papers), Pancreatic and Hepatic Oncology Research (2 papers), Cancer Genomics and Diagnostics (2 papers), Cancer Mechanisms and Therapy (2 papers), Ferroptosis and cancer prognosis (2 papers) and Lung Cancer Treatments and Mutations (2 papers). The work is most often cited by research in Hepatology (465 citations), Oncology (359 citations) and Pathology and Forensic Medicine (154 citations). Damir Begic has collaborated with scholars based in Spain, United States and Japan. Frequent co-authors include Richard S. Finn, Masatoshi Kudo, Bruno Sangro, Jaclyn Neely, Julien Edeline, Thomas Yau, Philippe Merle, James J. Harding, Ann‐Lii Cheng and Philippe Mathurin. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.